<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920226-0129</DOCNO><DOCID>920226-0129.</DOCID><HL>   Technology:   Medarex Drug Trials Approved</HL><DATE>02/26/92</DATE><SO>WALL STREET JOURNAL (J), PAGE B6</SO><CO>   MEDX</CO><MS>TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>SCIENCE andamp; TECHNOLOGY (SCN)</NS><GV>FOOD AND DRUG ADMINISTRATION (FDA)</GV><RE>NEW JERSEY (NJ)NORTH AMERICA (NME)PENNSYLVANIA (PA)UNITED STATES (US)</RE><LP>   PRINCETON, N.J. -- Medarex Inc. said it receivedregulatory approval from the Food and Drug Administration toproceed with human clinical trials of its new drug designedto treat a form of leukemia.   The monoclonal antibody-based drug, MDX-11, is given inconjunction with traditional chemotherapy for acute myeloidleukemia. The MDX-11 targets and destroys the residual cancercells that may remain following chemotherapy treatment, thecompany said.</LP><TEXT>   The trials will be directed from the University ofPittsburgh's medical school, and will include about 30 to 50leukemia patients who have relapsed after treatment. Medarexsaid acute myeloid leukemia afflicts about 11,000 newpatients a year in the U.S.</TEXT></DOC>